Ital TBS : C.E.&I.T S.p.A. has sold ordinary shares of TBS Group

Under the AIM Italia Issuers Regulations, TBS Group (the "Company") announces that C.E.&I.T

S.p.A., the main shareholder of TBS Group, with registered office in Trieste in via G. Gallina 4,

sold to Biovalley Investments S.p.A. on 26.08.2016 out of business, 34,200 ordinary shares of

TBS Group at an average price of € 1.599 per share, for a total amount of € 54,686, equivalent

to approximately 0.08% of the ordinary share capital of the Company.

Subsequent to this transaction, C.E.&I.T S.p.A. has reduced its shareholding in the TBS Group

from 20.69% to 20.61%.

C.E.&I.T S.p.A. is a financial company in which some managers at TBS Group have indirect

holdings as well as other third-party shareholders.

Furthermore, it is stated that:

•Mr Diego Bravar, Chairman of the Board of Directors of the Company, who held an

indirect holding of 1.63% in TBS Group, through a direct holding of 65.97% in Biovalley

Investments Spa which held in its turn an 11.95% stake in C.E.&I.T S.p.A. and a 0.08%

stake in TBS Group, has brought his indirect holding to 1.68%. The absolute value of

these operations amounts to € 36,075.13.

•Mr Nicola Pangher, General Manager of the "Medical Devices and ICT systems

International" Business Unit of the Company, who had a 3.91% stake in TBS Group,

through the direct holding of 69.76% of Biobit S.r.l. which in turn holds a stake of

27.10% in C.E.&I.T S.p.A., brought his holding to 3.90%. The absolute value of these

operations amounts to € 10,340.53.

TBS Group, listed on the AIM Italia, designs and manages outsourced clinical engineering and

ICT services, designs and provides integrated e-Health and e-Government solutions and

integrated systems of medical equipment, in order to make the use of biomedical and ICT

technologies safer and more effective. The Group's offer is aimed at innovating processes in the

health and social facilities, both public and private, and at reclassifying costs of services

supplied. With registered offices in Trieste at AREA Science Park and revenues totaling 233.8

million euros in 2015, the Group is present in 20 countries and operates with over 2,400

employees, in over 20 specialist centres and in more than 300 on site workshops linked to over

1,000 hospitals and other public and private bodies.

For further information:www.tbsgroup.com

TBS Group S.p.A.

Investor Relator

Stefano Beorchia

tel.: [phone]

[e-mail]

Trieste, 30 August 2016